Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 20/20 | 0.45 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15706812 | 0.91 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL14157643 | 0.91 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL14159650 | 0.86 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL15706766 | 0.86 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL14157726 | 0.86 | HSD11B1 (0.52) | HSD11B1HSD11B2 | |
| SCHEMBL15706740 | 0.84 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL15667735 | 0.84 | HSD11B1 (0.56) | HSD11B1HSD11B2 | |
| SCHEMBL15666804 | 0.83 | HSD11B1 (0.54) | HSD11B1HSD11B2 | |
| SCHEMBL15706773 | 0.83 | HSD11B1 (0.54) | HSD11B1HSD11B2 | |
| SCHEMBL14157727 | 0.78 | HSD11B1 (0.54) | HSD11B1HSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2699560-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK Biopharmaceuticals Co., Ltd. (KR) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012169863-A2 | 5-CARBAMOYL-ADAMANTAN-2-YL AMIDE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AND PREPARATION PROCESS THEREOF | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2012-12-13 | — | — | WO | disclosed |